Buserelin
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Clinical data | |
---|---|
Synonyms | D-Ser(Tbu)6EA10LHRH |
Pregnancy category |
|
Routes of administration | implant, intranasal |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 72 to 80 minutes |
Excretion | Renal |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C62H90N16O15 |
Molar mass | 1299.48 g/mol |
WikiDoc Resources for Buserelin |
Articles |
---|
Most recent articles on Buserelin |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Buserelin at Clinical Trials.gov Clinical Trials on Buserelin at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Buserelin
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Buserelin Discussion groups on Buserelin Directions to Hospitals Treating Buserelin Risk calculators and risk factors for Buserelin
|
Healthcare Provider Resources |
Causes & Risk Factors for Buserelin |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Buserelin is a Gonadotropin-releasing hormone agonist (GnRH agonist). By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, buserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
It is normally delivered via a nasal spray but is also available as an injection.
Buserelin acetate is marketed by Sanofi-Aventis under the brand name Suprefact.
Template:Sex hormones Template:SIB de:Buserelin sv:Buserelinacetat
- Pages with script errors
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- GnRH agonists
- Endocrinology